Zobrazeno 1 - 10
of 15
pro vyhledávání: '"John Lepore"'
HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury
Autor:
Andrew N. Billin, Samuel E. Honeycutt, Alan V. McDougal, Jaclyn P. Kerr, Zhe Chen, Johannes M. Freudenberg, Deepak K. Rajpal, Guizhen Luo, Henning Fritz Kramer, Robert S. Geske, Frank Fang, Bert Yao, Richard V. Clark, John Lepore, Alex Cobitz, Ram Miller, Kazunori Nosaka, Aaron C. Hinken, Alan J. Russell
Publikováno v:
Skeletal Muscle, Vol 8, Iss 1, Pp 1-14 (2018)
Abstract Background In muscular dystrophy and old age, skeletal muscle repair is compromised leading to fibrosis and fatty tissue accumulation. Therefore, therapies that protect skeletal muscle or enhance repair would be valuable medical treatments.
Externí odkaz:
https://doaj.org/article/e1f73e6f4eda4a62a3d79d3777de791e
Autor:
Jin Zhou, Jie Li, Daniel M Rosenbaum, Jian Zhuang, Carrie Poon, Pu Qin, Katrina Rivera, John Lepore, Robert N Willette, Erding Hu, Frank C Barone
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0184049 (2017)
There is interest in pharmacologic preconditioning for end-organ protection by targeting the HIF system. This can be accomplished by inhibition of prolyl 4-hydroxylase (PHD). GSK360A is an orally active PHD inhibitor that has been previously shown to
Externí odkaz:
https://doaj.org/article/cb1b846706204171ab5a6168e334d25c
Autor:
Andrew N. Billin, Samuel E. Honeycutt, Alan V. McDougal, Jaclyn P. Kerr, Zhe Chen, Johannes M. Freudenberg, Deepak K. Rajpal, Guizhen Luo, Henning Fritz Kramer, Robert S. Geske, Frank Fang, Bert Yao, Richard V. Clark, John Lepore, Alex Cobitz, Ram Miller, Kazunori Nosaka, Aaron C. Hinken, Alan J. Russell
Publikováno v:
Skeletal Muscle, Vol 8, Iss 1, Pp 1-1 (2018)
Following publication of the original article [1], the authors flagged that there is a discrepancy with the Availability of data and materials statement on page 12 of the article.
Externí odkaz:
https://doaj.org/article/d03026fdb79744668aebcc8fa062fee1
Publikováno v:
Organic Process Research & Development. 24:2762-2771
The selection of regulatory starting materials (RSMs) is a critical step in determining where the drug substance manufacturing process begins as it relates to the submission and approval of the com...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::991d64ea17fbdeb8663436617d202fb7
https://doi.org/10.1021/acs.oprd.0c00341
https://doi.org/10.1021/acs.oprd.0c00341
Autor:
Carla V. Luciani, Lindsay A. Hobson, Batool Ahmed Omer, Kevin D. Seibert, Sushil K. Srivastava, Matt E. Popkin, John Lepore
Publikováno v:
Journal of Pharmaceutical Innovation. 14:1-14
A series of case histories from IQ consortium member companies will be presented to exemplify how the application of the ICH Q11 vision for enhanced Quality by Design (QbD) development of the active pharmaceutical ingredient (API) can lead to differe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b7d4d6c0bf37c4bd4f9e5ec3ab9ff17
https://doi.org/10.1007/s12247-018-9340-2
https://doi.org/10.1007/s12247-018-9340-2
Autor:
Phil J. Borman, John Lepore, Sushil K. Srivastava, Nathan D. Ide, John Donaubauer, Steven Tymonko, Matt E. Popkin, Lindsay A. Hobson, Kevin D. Seibert, Timothy Curran, Batool Ahmed Omer, Jeffrey M. Kallemeyn, Looker Adam
Publikováno v:
Journal of Pharmaceutical Innovation. 13:367-372
This paper by IQ consortium member companies will describe how the application of the ICH Q11 vision for enhanced QbD development can lead to flexibility through differentiated outcomes for elements of API manufacture, such as the control strategy an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62d076d7d103e30887516e50a28d8f9a
https://doi.org/10.1007/s12247-018-9339-8
https://doi.org/10.1007/s12247-018-9339-8
Publikováno v:
Journal of Pharmaceutical Innovation. 13:283-285
ICH guidelines Q8/11, Q9, and Q10 introduced risk-based approaches and enhanced scientific understanding as an opportunity to encourage continuous process improvement for pharmaceutical manufacturing. Conceptually, Quality by Design (QbD) promised to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::407d61fde409e0e30b25742c8e46abb8
https://doi.org/10.1007/s12247-018-9338-9
https://doi.org/10.1007/s12247-018-9338-9
Autor:
Nicholas Murray Thomson, John Lepore, Carla V. Luciani, Sushil K. Srivastava, Erwin Irdam, Robert A. Singer, Kevin D. Seibert, William F. Kiesman, Luke Schenck
Publikováno v:
Organic Process Research & Development. 19:935-948
A series of case histories from IQ consortium member companies are presented in order to exemplify many of the different elements of drug substance control strategies that are required in order to ensure process performance and product quality. Contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62c9cef8f5be7697fc374b346e5194b4
https://doi.org/10.1021/acs.oprd.5b00146
https://doi.org/10.1021/acs.oprd.5b00146
Publikováno v:
The AAPS journal. 19(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64707a571615502203fcd55b45774b8f
https://pubmed.ncbi.nlm.nih.gov/27488208
https://pubmed.ncbi.nlm.nih.gov/27488208
Autor:
Spavins James Christian, John Lepore
Publikováno v:
Journal of Pharmaceutical Innovation. 3:79-87
This paper describes progress made by the Design Space Task Team within the ISPE Product Quality Lifecycle Implementation (PQLI) initiative. It is intended to provide approaches to the rational development of Design Space, as well as background on De
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19db2b8d869731acc4e94f80fe921db1
https://doi.org/10.1007/s12247-008-9034-2
https://doi.org/10.1007/s12247-008-9034-2